Inhibition of monoamine oxidase by viloxazine in rats.

Article Details

Citation

Copy to clipboard

Martinez C, Dominiak P, Kees F, Grobecker H

Inhibition of monoamine oxidase by viloxazine in rats.

Arzneimittelforschung. 1986 May;36(5):800-3.

PubMed ID

2425816 [ View in PubMed

]

Abstract

Biochemical and pharmacological investigations about the effect of the antidepressant drug viloxazine (Vivalan) on catecholamine metabolism in rats led to the following results: Viloxazine exerts a dose and time dependent inhibition of monoamine oxidase activity of brain and liver mitochondrial fraction and tissue homogenates of hypothalamus, heart, liver, and adrenal glands, both in vitro and after oral and parenteral administration in vivo. Consequently, an increase in catecholamine concentrations in brain of rats could be observed after pretreatment with viloxazine. In addition brain serotonin concentrations rose and 5-hydroxy-indoleacetic acid was diminished. However, characterization of inhibition of monoamine oxidase activity by viloxazine in vitro revealed: Compared to the specific inhibitors clorgyline for MAO-A- and pargyline for MAO-B-activity, viloxazine was a very weak inhibitor both for MAO-A and MAO-B in vitro. The type of inhibition was competitive and reversible. From the presented results and the results obtained by other laboratories it is concluded that inhibition of monoamine oxidase activity by viloxazine, although clearly demonstrated in animal experiments, may not be the only mechanism for an antidepressant action of the drug in man.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Viloxazine	Amine oxidase [flavin-containing] A	Protein	Humans	Unknown	Inhibitor	Details
Viloxazine	Amine oxidase [flavin-containing] B	Protein	Humans	Unknown	Inhibitor	Details